UPLOAD Filing
ONCOLYTICS BIOTECH INC
Date: April 1, 2026 · CIK: 0001129928 · Accession: 0000000000-26-003301
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294811
Letter
Re: Oncolytics Biotech Inc. Registration Statement on Form S-3 Filed April 1, 2026 File No. 333-294811 Dear Jared Kelly:
April 1, 2026
Jared Kelly Chief Executive Officer Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Christopher J. Clark, Esq.
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
April 1, 2026
Jared Kelly
Chief Executive Officer
Oncolytics Biotech Inc.
4350 Executive Drive, Suite 325
San Diego, California 92121
Re: Oncolytics Biotech Inc.
Registration Statement on Form S-3
Filed April 1, 2026
File No. 333-294811
Dear Jared Kelly:
This is to advise you that we have not reviewed and will not review your
registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Christopher J. Clark, Esq.
</TEXT>
</DOCUMENT>